R&G PharmaStudies Resultados de beneficios anteriores
Pasado controles de criterios 2/6
R&G PharmaStudies has been growing earnings at an average annual rate of 13.2%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 10.6% per year. R&G PharmaStudies's return on equity is 6.8%, and it has net margins of 16%.
Información clave
13.2%
Tasa de crecimiento de los beneficios
10.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 26.8% |
| Tasa de crecimiento de los ingresos | 10.6% |
| Rentabilidad financiera | 6.8% |
| Margen neto | 16.0% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero R&G PharmaStudies. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 759 | 121 | 133 | 56 |
| 30 Jun 24 | 738 | 135 | 126 | 55 |
| 31 Mar 24 | 738 | 157 | 109 | 53 |
| 31 Dec 23 | 721 | 163 | 99 | 53 |
| 30 Sep 23 | 694 | 155 | 82 | 53 |
| 30 Jun 23 | 673 | 138 | 85 | 52 |
| 31 Mar 23 | 628 | 115 | 80 | 51 |
| 01 Jan 23 | 638 | 113 | 79 | 50 |
| 30 Sep 22 | 634 | 112 | 76 | 48 |
| 30 Jun 22 | 640 | 110 | 77 | 46 |
| 31 Mar 22 | 632 | 101 | 81 | 44 |
| 01 Jan 22 | 608 | 99 | 79 | 41 |
| 31 Dec 20 | 484 | 84 | 65 | 35 |
| 31 Dec 19 | 425 | 83 | 57 | 31 |
| 31 Dec 15 | 142 | 24 | 35 | 0 |
| 31 Dec 14 | 96 | 14 | 28 | 0 |
| 31 Dec 13 | 78 | 12 | 19 | 0 |
Ingresos de calidad: 301333 has high quality earnings.
Margen de beneficios creciente: 301333's current net profit margins (16%) are lower than last year (22.4%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 301333's earnings have grown by 13.2% per year over the past 5 years.
Acelerando crecimiento: 301333's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Beneficios vs. Industria: 301333 had negative earnings growth (-22.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).
Rentabilidad financiera
Alta ROE: 301333's Return on Equity (6.8%) is considered low.